ERBB2 and non-small cell lung carcinoma: A phase II trial of dacomitinib, an irreversible TKI with activity against both EGFR and HER2, revealed that only 12% of NSCLC patients harboring HER2 exon-20 mutations experienced a PR, with none of those harboring a YVMA insertion showing a response [17].